ALX Oncology Holdings Inc
ALXO
NASDAQ
Biotechnology
$1.96
USD
+0.02 (+1.03%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $272.41M
Volume 584.1K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-80.89M
TTM
+30.6%
YoY
Operating Cash Flow
$-70.78M
TTM
+32.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.5 | 5.1 | 5.4 | 5.4 | 5.1 |
Other Operating Expenses | 3.2 | 0.0 | 0.0 | 0.0 | -0.2 |
Total Operating Expenses | 26.6 | 22.5 | 23.0 | 19.0 | 18.0 |
Operating Income | -26.6 | -22.5 | -23.0 | -19.0 | -18.0 |
EBITDA | -23.3 | -22.4 | -22.9 | -18.8 | -18.2 |
Other Income / Expense | -0.0 | -0.0 | -0.0 | 0.2 | -1.2 |
Total Other Income / Expense | 0.7 | 0.4 | 0.2 | 1.0 | 0.1 |
Income Before Income Taxes | -25.9 | -22.1 | -22.8 | -17.9 | -18.0 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -25.9 | -22.1 | -22.8 | -17.9 | -18.0 |
Consolidated Net Income / Loss | -25.9 | -22.1 | -22.8 | -17.9 | -18.0 |
Net Income Attributable to Common Shareholders | -25.9 | -22.1 | -22.8 | -17.9 | -18.0 |
Basic EPS | -$0.49 | -$0.41 | -$0.42 | -$0.17 | -$0.13 |
Diluted EPS | -$0.49 | -$0.41 | -$0.42 | -$0.17 | -$0.13 |
Basic Shares Outstanding | 53.4M | 53.6M | 54.3M | 104.6M | 135.6M |
Diluted Shares Outstanding | 53.4M | 53.6M | 54.3M | 104.6M | 135.6M |